Log In

Yaakov Nahmias Edit Profile

Professor , Biomedical engineer

Yaakov Nahmias, Israeli biomedical engineer. Achievements include discovery of grapefruit flavonoid for HCV treatment. Recipient Mentored Research Scientist Career award, National Institute Health, 2008.


Nahmias, Yaakov was born on April 2, 1974 in Tel Aviv, Israel.


Bachelor of Science, Technion, Haifa, Israel, 1999. Doctor of Philosophy, University Minnesota, Minneapolis, 2004. Postdoctoral, Harvard Medical School, Boston, Massachusetts, 2006.


Yaakov Nahmias received his B.Sc. in Chemical Engineering and Biology from the Technion – Israel Institute of Technology, graduating Magna Cum Laude. He completed his PhD at the University of Minnesota with David Odde, and his postdoctoral training at Harvard Medical School with Martin Yarmush. In 2006, he became an independent investigator at Harvard Medical School, winning a NIH Scientist Development Award (K01).

In 2012, Nahmias together with Chaim Lotan, established BioDesign Israel, a multi-disciplinary program in medical innovation taught at the Hebrew University of Jerusalem and its affiliated Hadassah Medical Center. Nahmias is a liver biologist and a biomedical engineer who took part in the development of Lodamin, the first oral, broad-spectrum angiogenesis inhibitor and the first decellularization of an intact liver for transplantation. His own work showed that the Hepatitis C Virus (HCV) assembles on VLDL and that its production is blocked by the grapefruit flavonoid naringenin.

Nahmias' work is leading to a growing understanding of the role of diet and nutrition on liver metabolism, including the first demonstration that gut bacteria affect liver development after birth, and explaining the toxic affects of acetaminophen using liver-on-chip technology.


  • He is a co-founder of Israel’s BioDesign Medical Innovation program, recently listed as a major reason for Boston Scientific's continued investment in Israel. In 2014, he won the Rappaport Prize for Biomedical Sciences for his “groundbreaking work on liver tissue engineering” and the “development of nanotechnology therapies for the treatment of diabetes”. Nahmias moved to the Hebrew University of Jerusalem in 2009, where he won a major European Council (ERC) Starting Grant, and founded the Alexander Grass Center for Bioengineering.

    Spin offs from the BioDesign program raised over $1.2 million in investments, won national awards and were featured in MassChallenge.


Nahmias is the founding director of the Alexander Grass Center for Bioengineering and an affiliated member of the NIH-funded BioMEMS Resource Center at Massachusetts General Hospital. Nahmias edited a book titled Microdevices in Biology and Medicine, and is currently serving as a technology consultant for L’Oreal, and a member of the European Council panel for applied life sciences and biotechnology. In 2010, Nahmias became a Golda Meir fellow and a member of the ERC Starting Grant panel on applied life sciences and biotechnology (LS9).